SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-036343
Filing Date
2020-11-12
Accepted
2020-11-12 07:00:50
Documents
59
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0920_protaratherapeutics.htm 10-Q 852870
2 AMENDMENT TO AGREEMENT, BY AND BETWEEN CHUGAI PHARMACEUTICAL CO., LTD. AND THE R f10q0920ex10-1_protara.htm EX-10.1 29464
3 CERTIFICATION f10q0920ex31-1_protara.htm EX-31.1 12181
4 CERTIFICATION f10q0920ex31-2_protara.htm EX-31.2 11996
5 CERTIFICATION f10q0920ex32-1_protara.htm EX-32.1 6957
  Complete submission text file 0001213900-20-036343.txt   3840157

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE tara-20200930.xml EX-101.INS 571126
7 XBRL SCHEMA FILE tara-20200930.xsd EX-101.SCH 51482
8 XBRL CALCULATION FILE tara-20200930_cal.xml EX-101.CAL 44879
9 XBRL DEFINITION FILE tara-20200930_def.xml EX-101.DEF 161998
10 XBRL LABEL FILE tara-20200930_lab.xml EX-101.LAB 322261
11 XBRL PRESENTATION FILE tara-20200930_pre.xml EX-101.PRE 250560
Mailing Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014
Business Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 201303270
SIC: 2836 Biological Products, (No Diagnostic Substances)